General Pharmacology Practice Questions

Q: When used in the management of inflammatory disorders, glucocorticoids are likely to cause which of the following?

Increase in intraocular pressure. **Explanation:** Glucocorticoids (GCs) are steroid hormones that exert widespread metabolic and physiological effects. The correct answer is **D. Increase in intraocular pressure (IOP).** **Why it is correct:** Glucocorticoids can cause ocular hypertension and secondary open-angle glaucoma. They increase IOP by increasing the resistance to aqueous humor outflow through the trabecular meshwork. This occurs due to the accumulation of glycosaminoglycans and specific proteins (like myocilin) in the trabecular meshwork, which obstructs drainage. **Why the other options are incorrect:** * **A. Hypoglycemia:** GCs are "diabetogenic." They stimulate gluconeogenesis and decrease peripheral glucose uptake, leading to **hyperglycemia**, not hypoglycemia. * **B. Decreases in blood pressure:** GCs have weak mineralocorticoid activity, leading to sodium and water retention. They also sensitize vascular smooth muscle to catecholamines, typically causing **hypertension**. * **C. Anabolic actions in wound healing:** GCs are primarily **catabolic**. They inhibit fibroblast proliferation and collagen synthesis, which leads to delayed wound healing and skin thinning (striae). **High-Yield Clinical Pearls for NEET-PG:** * **Cushingoid Side Effects:** Remember the mnemonic **"CUSHINGOID"**: **C**ataracts (Posterior Subcapsular), **U**lcers (Peptic), **S**triate/Skin thinning, **H**ypertension/Hirsutism, **I**mmunosuppression, **N**ecrosis (Avascular necrosis of femoral head), **G**lucose elevation, **O**steoporosis, **I**OP increase, **D**epression/Psychosis. * **Osteoporosis:** GCs are the most common cause of drug-induced osteoporosis (they inhibit osteoblasts and decrease calcium absorption). * **Growth:** In children, GCs cause growth retardation due to interference with growth hormone action and epiphyseal closure.

Q: Drugs used for rare diseases are known as:

Orphan drugs. **Explanation:** **1. Why "Orphan Drugs" is correct:** Orphan drugs are biological products or medicines intended for the diagnosis, prevention, or treatment of **rare diseases** (e.g., Cystic Fibrosis, Gaucher’s disease, Thalidomide for Leprosy). These diseases affect a very small percentage of the population. Because the market for these drugs is limited, pharmaceutical companies find them commercially non-viable to develop under normal conditions. To encourage their production, governments provide incentives like tax credits, patent extensions, and simplified marketing authorization. **2. Why other options are incorrect:** * **Rare drugs:** This is a distractor term. While the diseases are rare, the pharmacological classification for the treatment is "Orphan drug," not "rare drug." * **Over-the-counter (OTC) drugs:** These are non-prescription drugs that can be sold directly to a consumer without a doctor's note (e.g., Paracetamol, Antacids). They are used for common, self-limiting conditions, the opposite of rare diseases. * **Emergency drugs:** These are life-saving medications required for immediate administration in acute conditions (e.g., Adrenaline in anaphylaxis, Atropine in organophosphate poisoning). Their classification is based on the urgency of use, not the prevalence of the disease. **3. High-Yield Clinical Pearls for NEET-PG:** * **Definition Criteria:** In the USA, a rare disease is defined as one affecting fewer than **200,000 people**. * **Examples of Orphan Drugs:** * **Digoxin Immune Fab:** For Digoxin toxicity. * **Fomepizole:** For Methanol poisoning. * **Amphotericin B:** For Visceral Leishmaniasis (Kala-azar). * **Thalidomide:** For Type 2 Lepra reaction (ENL) [1]. * **Regulatory Act:** The Orphan Drug Act was first passed in the USA in 1983.

Q: What is the duration of Phase IV in clinical trials?

Indefinite duration. ### Explanation **Correct Answer: D. Indefinite duration** **1. Why "Indefinite duration" is correct:** Phase IV clinical trials, also known as **Post-Marketing Surveillance (PMS)**, begin after a drug has been approved by regulatory authorities (like the FDA or CDSCO) and is available on the market. Unlike Phases I, II, and III, which have specific protocols and fixed timelines to establish safety and efficacy for approval, Phase IV has no fixed endpoint. Its primary purpose is the continuous monitoring of the drug’s performance in the general population to detect **rare adverse effects**, long-term complications, and drug-drug interactions that may not have surfaced in the controlled, smaller cohorts of Phase III. As long as the drug remains on the market, Phase IV monitoring continues. **2. Why other options are incorrect:** * **Options A, B, and C:** These represent finite timeframes. While individual Phase IV *studies* might last 1–5 years, the **phase itself** is ongoing. Fixed durations are more characteristic of pre-marketing phases: * **Phase I:** Days to weeks. * **Phase II:** Months to ~2 years. * **Phase III:** 1 to 4 years. **3. High-Yield Clinical Pearls for NEET-PG:** * **Primary Goal:** To detect **Rare Adverse Events** (e.g., incidence < 1 in 10,000). * **Population:** Open-ended; includes special groups (elderly, children, pregnant women) usually excluded from earlier phases. * **Pharmacovigilance:** This is the core activity of Phase IV. It can lead to "Black Box Warnings" or the withdrawal of a drug (e.g., Rofecoxib due to cardiovascular risks). * **Phase V:** Sometimes used to describe translational research or population-level effectiveness studies, though not a standard regulatory term.

Q: All of the following induce liver microsomal enzymes except?

Metyrapone. **Explanation:** The core concept tested here is the distinction between **Enzyme Inducers** and **Enzyme Inhibitors** within the Cytochrome P450 (CYP450) system. **Why Metyrapone is the Correct Answer:** Metyrapone is a diagnostic drug used to test pituitary-adrenal function. Mechanistically, it acts as a **microsomal enzyme inhibitor**, specifically inhibiting the enzyme **11-β-hydroxylase**. This inhibition blocks the conversion of 11-deoxycortisol to cortisol. Because it inhibits rather than induces hepatic enzymes, it is the "except" in this list. **Analysis of Incorrect Options (Enzyme Inducers):** * **Phenobarbitone:** A classic, potent inducer of multiple CYP450 isoenzymes. It is often the "prototype" inducer mentioned in textbooks. * **Carbamazepine:** A well-known anti-epileptic that is a strong inducer; it is unique because it exhibits **auto-induction** (induces its own metabolism). * **Glutethimide:** An older sedative-hypnotic drug that is a documented hepatic microsomal enzyme inducer. **High-Yield Clinical Pearls for NEET-PG:** To remember common **Enzyme Inducers**, use the mnemonic **"GPRS Cell Phone"**: * **G**riseofulvin * **P**henytoin / **P**henobarbitone * **R**ifampicin (Most potent inducer) * **S**moking / **S**t. John’s Wort * **C**arbamazepine * **P**henobarbitone **Clinical Significance:** Enzyme induction leads to decreased plasma concentrations of co-administered drugs (e.g., failure of oral contraceptives or subtherapeutic warfarin levels), whereas inhibition (like with Metyrapone, Ketoconazole, or Cimetidine) leads to increased drug toxicity.

Q: Thalidomide is used in which of the following conditions?

All of the above. Thalidomide, once infamous for its teratogenic effects (phocomelia), has been repurposed in modern medicine due to its potent **anti-inflammatory, immunomodulatory, and anti-angiogenic** properties. It acts primarily by inhibiting Tumor Necrosis Factor-alpha (TNF-α) and modulating T-cell responses. **Explanation of Options:** * **Lepra Reaction (ENL):** Thalidomide is the drug of choice for Type 2 Lepra Reaction (Erythema Nodosum Leprosum). It effectively suppresses the systemic inflammatory response by inhibiting TNF-α. * **Multiple Myeloma:** It is a cornerstone in the treatment of refractory or newly diagnosed Multiple Myeloma. Its mechanism involves inhibiting angiogenesis in the bone marrow and inducing apoptosis of malignant plasma cells. * **Ulcerative Colitis:** Due to its TNF-α inhibitory action, thalidomide is used as an "off-label" or reserve treatment for refractory cases of Inflammatory Bowel Disease (IBD), including Ulcerative Colitis and Crohn’s disease, when standard therapies fail. **Clinical Pearls for NEET-PG:** 1. **Mechanism:** Inhibition of TNF-α and IL-12; stimulation of T-cells (CD8+); and anti-angiogenic activity (via inhibition of VEGF and bFGF). 2. **Teratogenicity:** It is a category X drug. It causes **Phocomelia** (seal-like limbs) by inhibiting angiogenesis in developing limb buds. 3. **STEPS Program:** Due to its high teratogenic risk, it is prescribed under a restricted distribution program (System for Thalidomide Education and Prescribing Safety). 4. **Side Effects:** Peripheral neuropathy (most common dose-limiting toxicity), sedation, and increased risk of venous thromboembolism (especially when used with dexamethasone in Myeloma).

Q: Cyclosporine inhibits which of the following?

T lymphocyte proliferation. **Explanation:** **Mechanism of Action (Why A is correct):** Cyclosporine is a potent **calcineurin inhibitor**. Under normal physiological conditions, an increase in intracellular calcium activates calcineurin (a phosphatase). Calcineurin then dephosphorylates the **Nuclear Factor of Activated T-cells (NFAT)**, allowing it to enter the nucleus and initiate the transcription of **Interleukin-2 (IL-2)**. IL-2 is the primary cytokine responsible for the proliferation and differentiation of T lymphocytes. By binding to cyclophilin, Cyclosporine forms a complex that inhibits calcineurin, thereby blocking IL-2 production and specifically halting **T lymphocyte proliferation**. **Analysis of Incorrect Options:** * **Option B & C:** Cyclosporine is highly selective for T-cells. It does not significantly inhibit B lymphocyte proliferation directly, as B-cell activation involves different signaling pathways that are less dependent on the calcineurin-NFAT axis. * **Option D:** While Cyclosporine may have minor downstream effects on the immune cascade, its primary and therapeutic target is the T-helper cell (CD4+), not Natural Killer (NK) cells. **High-Yield Clinical Pearls for NEET-PG:** * **Therapeutic Uses:** Prevention of graft-versus-host disease (GVHD) in organ transplants and treatment of autoimmune conditions like rheumatoid arthritis and psoriasis. * **Adverse Effects (The "H" Mnemonic):** **H**ypertension, **H**yperplasia of gums (gingival hyperplasia), **H**irsutism, and **H**yperkalemia. * **Most Serious Side Effect:** Nephrotoxicity (dose-related and usually reversible). * **Metabolism:** It is metabolized by **CYP3A4**; therefore, grapefruit juice (an inhibitor) can increase its toxicity.

Q: A patient requires ceftriaxone 180 mg. You have a 2 mL syringe with 10 divisions per mL. The vial contains 500 mg/5 mL of ceftriaxone. How many divisions in the 2 mL syringe will you fill to give 180 mg ceftriaxone?

18. ### Explanation This question tests the ability to perform **pharmaceutical calculations**, a vital skill for clinical practice and a high-yield area in General Pharmacology. **1. Why Option A is Correct:** To find the number of divisions, we follow a two-step calculation: * **Step 1: Calculate the volume required.** The vial concentration is $500\text{ mg}$ in $5\text{ mL}$, which simplifies to $100\text{ mg/mL}$. Using the formula: $\text{Volume} = \frac{\text{Desired Dose}}{\text{Concentration on Hand}}$ $\text{Volume} = \frac{180\text{ mg}}{100\text{ mg/mL}} = \mathbf{1.8\text{ mL}}$ * **Step 2: Convert volume into syringe divisions.** The syringe has $10\text{ divisions per mL}$. Total divisions = $\text{Volume (mL)} \times \text{Divisions per mL}$ Total divisions = $1.8\text{ mL} \times 10 = \mathbf{18\text{ divisions}}$ **2. Why the Other Options are Incorrect:** * **Option B (1.8):** This represents the volume in **milliliters (mL)**, not the number of divisions. * **Option C (20):** This would be the total capacity of the $2\text{ mL}$ syringe ($2 \times 10 = 20$), delivering $200\text{ mg}$. * **Option D (2):** This is a mathematical error, likely from miscalculating the concentration or the division factor. **3. Clinical Pearls & High-Yield Facts:** * **Ceftriaxone Specifics:** It is a third-generation cephalosporin. **High-yield fact:** Avoid diluting Ceftriaxone with **Calcium-containing solutions** (like Ringer’s Lactate) as it can form fatal precipitates, especially in neonates. * **Calculation Tip:** Always double-check the "units" requested (mL vs. mg vs. divisions). In NEET-PG, "divisions" usually refers to the smallest markings on a syringe (often $0.1\text{ mL}$ in a $2\text{ mL}$ or $5\text{ mL}$ syringe). * **Pediatric Dosing:** Most errors occur during the conversion from stock concentration to the final volume; always use the $C_1V_1 = C_2V_2$ or the "Desired/Have" formula.

Question 1

When used in the management of inflammatory disorders, glucocorticoids are likely to cause which of the following?

Accepted Answer

Increase in intraocular pressure

Answer

Hypoglycemia

Answer

Decreases in blood pressure

Answer

Anabolic actions in wound healing

Question 2

Drugs used for rare diseases are known as:

Accepted Answer

Orphan drugs

Answer

Rare drugs

Answer

Over-the-counter drugs

Answer

Emergency drugs

Question 3

Which of the following represents the newest therapeutic drug development agent?

Accepted Answer

Micro RNA

Answer

Ribozyme

Answer

SnRNA

Answer

Retro RNA

Question 4

What is pharmacokinetics?

Accepted Answer

The study of absorption, distribution, binding, storage, biotransformation, and excretion of drugs.

Answer

The study of the physiological and biochemical effects of drugs.

Answer

The application of pharmacological information together with knowledge of the disease.

Answer

The scientific study of drugs in humans.

Question 5

What is the duration of Phase IV in clinical trials?

Accepted Answer

Indefinite duration

Answer

3-5 years

Answer

1-3 years

Answer

1 year

Question 6

All of the following induce liver microsomal enzymes except?

Accepted Answer

Metyrapone

Answer

Glutethimide

Answer

Carbamazepine

Answer

Phenobarbitone

Question 7

Which of the following statements is NOT true of local anesthetics?

Accepted Answer

The local anesthetic binds to its receptor mainly when the Na+ channel is in the resting state.

Answer

The local anesthetic is required in the unionized form for penetrating the neuronal membrane.

Answer

The local anesthetic approaches its receptor only from the intraneuronal face of the Na+ channel.

Answer

The local anesthetic combines with its receptor in the ionized cationic form.

Question 8

Thalidomide is used in which of the following conditions?

Accepted Answer

All of the above

Answer

Lepra reaction

Answer

Multiple Myeloma

Answer

Ulcerative Colitis

Question 9

Cyclosporine inhibits which of the following?

Accepted Answer

T lymphocyte proliferation

Answer

B lymphocyte proliferation

Answer

Both T and B lymphocyte proliferation

Answer

NK cells only

Question 10

A patient requires ceftriaxone 180 mg. You have a 2 mL syringe with 10 divisions per mL. The vial contains 500 mg/5 mL of ceftriaxone. How many divisions in the 2 mL syringe will you fill to give 180 mg ceftriaxone?

Accepted Answer

18

Answer

1.8

Answer

20

Answer

2

General Pharmacology — MCQs

General Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?